<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title-group><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title></journal-title-group><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5536237</article-id><article-id pub-id-type="doi">10.2147/COPD.S138720</article-id><article-id pub-id-type="publisher-id">copd-12-2179</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>The association of tidal EFL with exercise performance, exacerbations, and death in COPD</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aarli</surname><given-names>Bernt Boegvald</given-names></name><xref ref-type="aff" rid="af1-copd-12-2179">1</xref><xref ref-type="aff" rid="af2-copd-12-2179">2</xref><xref ref-type="corresp" rid="c1-copd-12-2179"/></contrib><contrib contrib-type="author"><name><surname>Calverley</surname><given-names>Peter MA</given-names></name><xref ref-type="aff" rid="af3-copd-12-2179">3</xref></contrib><contrib contrib-type="author"><name><surname>Jensen</surname><given-names>Robert L</given-names></name><xref ref-type="aff" rid="af4-copd-12-2179">4</xref></contrib><contrib contrib-type="author"><name><surname>Dellac&#x000e0;</surname><given-names>Raffaele</given-names></name><xref ref-type="aff" rid="af5-copd-12-2179">5</xref></contrib><contrib contrib-type="author"><name><surname>Eagan</surname><given-names>Tomas ML</given-names></name><xref ref-type="aff" rid="af1-copd-12-2179">1</xref><xref ref-type="aff" rid="af2-copd-12-2179">2</xref></contrib><contrib contrib-type="author"><name><surname>Bakke</surname><given-names>Per S</given-names></name><xref ref-type="aff" rid="af1-copd-12-2179">1</xref></contrib><contrib contrib-type="author"><name><surname>Hardie</surname><given-names>Jon A</given-names></name><xref ref-type="aff" rid="af1-copd-12-2179">1</xref></contrib></contrib-group><aff id="af1-copd-12-2179">
<label>1</label>Department of Clinical Science, University of Bergen</aff><aff id="af2-copd-12-2179">
<label>2</label>Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway</aff><aff id="af3-copd-12-2179">
<label>3</label>Clinical Science Centre, University Hospital Aintree, Liverpool, UK</aff><aff id="af4-copd-12-2179">
<label>4</label>LDS Hospital, Pulmonary Division, Salt Lake City, UT, USA</aff><aff id="af5-copd-12-2179">
<label>5</label>TBM-Lab, Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano University, Milano, Italy</aff><author-notes><corresp id="c1-copd-12-2179">Correspondence: Bernt Boegvald Aarli, Department of Thoracic Medicine, Postboks 1400, Haukeland University Hospital, 5021 Bergen, Norway, Tel +47 9203 7838, Email <email>bernt_aarli@me.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>26</day><month>7</month><year>2017</year></pub-date><volume>12</volume><fpage>2179</fpage><lpage>2188</lpage><permissions><copyright-statement>&#x000a9; 2017 Aarli et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2017</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>Tidal expiratory flow limitation (EFL<sub>T</sub>) is frequently found in patients with COPD and can be detected by forced oscillations when within-breath reactance of a single-breath is &#x02265;0.28 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>. The present study explored the association of within-breath reactance measured over multiple breaths and EFL<sub>T</sub> with 6-minute walk distance (6MWD), exacerbations, and mortality.</p></sec><sec><title>Methods</title><p>In 425 patients, spirometry and forced oscillation technique measurements were obtained on eight occasions over 3 years. 6MWD was assessed at baseline and at the 3-year visit. Respiratory symptoms, exacerbations, and hospitalizations were recorded. A total of 5-year mortality statistics were retrieved retrospectively. We grouped patients according to the mean within-breath reactance <inline-formula><mml:math id="mm1"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, measured over several breaths at baseline, calculated as mean inspiratory&#x02013;mean expiratory reactance over the sampling period. In addition to the established threshold of EFL<sub>T</sub>, an upper limit of normal (ULN) was defined using the 97.5th percentile of <inline-formula><mml:math id="mm2"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, of the healthy controls in the study; 6MWDs were compared according to <inline-formula><mml:math id="mm3"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, as normal, &#x02265; ULN &#x0003c; EFL<sub>T</sub>, or &#x02265; EFL<sub>T</sub>. Annual exacerbation rates were analyzed using a negative binomial model in the three groups, supplemented by time to first exacerbation analysis, and dichotomizing patients at the ULN.</p></sec><sec><title>Results</title><p>In patients with COPD and baseline <inline-formula><mml:math id="mm4"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> below the ULN (0.09 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>), 6MWD was stable. 6MWD declined significantly in patients with <inline-formula><mml:math id="mm5"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula>. Worse lung function and more exacerbations were found in patients with COPD with <inline-formula><mml:math id="mm6"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula>, and patients with <inline-formula><mml:math id="mm7"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> had shorter time to first exacerbation and hospitalization. A significantly higher mortality was found in patients with <inline-formula><mml:math id="mm8"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> and FEV<sub>1</sub> &#x0003e;50%.</p></sec><sec><title>Conclusion</title><p>Patients with baseline <inline-formula><mml:math id="mm9"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> had a deterioration in exercise performance, more exacerbations, and greater hospitalizations, and, among those with moderate airway obstruction, a higher mortality. <inline-formula><mml:math id="mm10"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is a novel independent marker of outcome in COPD.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>forced oscillation technique</kwd><kwd>reactance</kwd><kwd>COPD</kwd><kwd>exacerbations</kwd><kwd>6-minute walk test</kwd><kwd>mortality</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>COPD is a major cause of morbidity and mortality, leading to an estimated 3.1 million deaths globally in 2012.<xref rid="b1-copd-12-2179" ref-type="bibr">1</xref> Although symptoms and exacerbation rate have been added to our assessment system of COPD,<xref rid="b2-copd-12-2179" ref-type="bibr">2</xref> spirometry remains an important tool in assessing severity and prognosis in this disease. Changes in the forced expiratory volume in 1 second (FEV<sub>1</sub>) are still the best indicator of disease progression and the risk of dying from COPD.<xref rid="b2-copd-12-2179" ref-type="bibr">2</xref>,<xref rid="b3-copd-12-2179" ref-type="bibr">3</xref> Yet, on an individual level, FEV<sub>1</sub> is an unreliable marker of morbidity, especially in early disease,<xref rid="b4-copd-12-2179" ref-type="bibr">4</xref>&#x02013;<xref rid="b6-copd-12-2179" ref-type="bibr">6</xref> and there is a need to identify alternative objective tests that can aid in stratifying the risk of further patient deterioration.</p><p>Patients who exhibit tidal expiratory flow limitation (EFL<sub>T</sub>) might be such a subgroup. EFL<sub>T</sub> occurs when increases in driving pressure fail to increase expiratory flow during resting tidal breathing and is most often seen in patients with severe COPD,<xref rid="b7-copd-12-2179" ref-type="bibr">7</xref>,<xref rid="b8-copd-12-2179" ref-type="bibr">8</xref> although it can occur with only moderate airway obstruction. Previous studies of EFL<sub>T</sub> in COPD have focused on its association with operating lung volume, exercise tolerance,<xref rid="b9-copd-12-2179" ref-type="bibr">9</xref>,<xref rid="b10-copd-12-2179" ref-type="bibr">10</xref> and its relation to breathlessness.<xref rid="b11-copd-12-2179" ref-type="bibr">11</xref>&#x02013;<xref rid="b13-copd-12-2179" ref-type="bibr">13</xref> It is not known whether EFL<sub>T</sub> can provide longer-term prognostic information in COPD.</p><p>EFL<sub>T</sub> can be detected by the forced oscillation technique (FOT).<xref rid="b14-copd-12-2179" ref-type="bibr">14</xref>,<xref rid="b15-copd-12-2179" ref-type="bibr">15</xref> When peripheral airways collapse on expiration, oscillatory pressure signals are prevented from reaching the alveoli. As this happens, the oscillatory compliance is reduced. Consequently, expiratory reactance (Xrs<sub>exp</sub>) becomes more negative than the inspiratory reactance (Xrs<sub>insp</sub>), leading to a within-breath reactance difference (&#x00394;Xrs). In the absence of EFL<sub>T</sub>, reactance measured in inspiration and in expiration is almost identical. The within-breath reactance difference (&#x00394;Xrs) cut-off of 0.28 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup> has been defined and validated to identify flow-limited breaths.<xref rid="b14-copd-12-2179" ref-type="bibr">14</xref>,<xref rid="b15-copd-12-2179" ref-type="bibr">15</xref> EFL<sub>T</sub> is not only linked to dyspnea in COPD,<xref rid="b11-copd-12-2179" ref-type="bibr">11</xref>,<xref rid="b16-copd-12-2179" ref-type="bibr">16</xref> but also to COPD exacerbations, where &#x00394;Xrs have been found to increase at the onset of COPD exacerbations and decrease when the exacerbation resolves.<xref rid="b17-copd-12-2179" ref-type="bibr">17</xref></p><p>In this study, we used forced oscillation technique to define EFL<sub>T</sub> in 425 patients with COPD. We hypothesized that the presence of EFL<sub>T</sub>, assessed by increased mean &#x00394;Xrs <inline-formula><mml:math id="mm11"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, would relate to changes in 6MWD, the risk of COPD exacerbations, and, possibly, mortality. We explored these hypotheses using baseline <inline-formula><mml:math id="mm12"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> as a predictor for future events. Patients with COPD with abnormally high <inline-formula><mml:math id="mm13"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, both above the upper limit of normal (ULN) and above the established threshold of EFL<sub>T</sub>, were investigated to determine whether they differed from those without evidence of tidal expiratory flow limitation.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="methods|subjects"><title>Study design and patients</title><p>The current data derive from the Bergen cohort of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study,<xref rid="b18-copd-12-2179" ref-type="bibr">18</xref> with additional patients enrolled from our clinical catchment area. Written informed consent was obtained from all study subjects. The study was approved by the regional ethics committee, REK vest (REK 165.08), and performed in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>; No: NTC00292552; <ext-link ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">www.ClinicalTrials.gov</ext-link>).<xref rid="b39-copd-12-2179" ref-type="bibr">39</xref></p><p>Inclusion criteria for patients with COPD were: age 40&#x02013;75 years, FEV<sub>1</sub> &#x0003c;80% predicted, FEV<sub>1</sub>/FVC &#x0003c;0.7, and a smoking history of &#x02265;10 pack-years. Study patients were evaluated every 6 months for 3 years with an additional visit at 3 months after baseline, totaling eight visits. The American Thoracic Society-Division of Lung Disease (ATS-DLD-78) questionnaire and the modified Medical Research Council dyspnea scale score (mMRC) were used to record respiratory symptoms.<xref rid="b19-copd-12-2179" ref-type="bibr">19</xref>,<xref rid="b20-copd-12-2179" ref-type="bibr">20</xref></p><p>Post-bronchodilator spirometry and oscillatory lung mechanics during tidal breathing were performed after inhalation of 0.4 mg salbutamol (GlaxoSmithKline, Ventolin, London, UK) according to American Thoracic Society/European Respiratory Society (ATS/ERS) international standards at each visit using a Jaeger MasterScope CT Impulse Oscillation System (Jaeger, Hoechberg, Germany).<xref rid="b21-copd-12-2179" ref-type="bibr">21</xref>,<xref rid="b22-copd-12-2179" ref-type="bibr">22</xref> Local reference values were used to determine the FEV<sub>1</sub>% predicted.<xref rid="b23-copd-12-2179" ref-type="bibr">23</xref> The FOT measurements were performed with the patient seated, cheeks supported, and wearing a nose clip. We performed three continuous measurements of 30 seconds, totaling 90 seconds of tidal volume breathing. Acceptability of measurements was determined using the ERS 2003 task force recommendations.<xref rid="b22-copd-12-2179" ref-type="bibr">22</xref></p><p><inline-formula><mml:math id="mm14"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> reactance was averaged over the 90-second sample, containing several breaths, and was calculated as follows: <inline-formula><mml:math id="mm15"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mtext>mean</mml:mtext></mml:mrow></mml:math></inline-formula> Xrs<sub>insp</sub> at 5 Hz &#x02013; mean Xrs<sub>exp</sub> at 5 Hz. Two cut-offs were investigated: the ULN defined as the 97.5th percentile of healthy controls in the Bergen cohort of the ECLIPSE study (<inline-formula><mml:math id="mm16"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mn>0.09</mml:mn><mml:mspace width="0.2em"/><mml:mtext>kPa</mml:mtext><mml:mo>&#x000b7;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mo>&#x000b7;</mml:mo><mml:msup><mml:mi mathvariant="normal">L</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>; <xref ref-type="supplementary-material" rid="SD1-copd-12-2179">Figure S1</xref>),<xref rid="b13-copd-12-2179" ref-type="bibr">13</xref> and at the established EFL<sub>T</sub> defining threshold for within-breath reactance, 0.28 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>, derived from single-breath analysis.<xref rid="b14-copd-12-2179" ref-type="bibr">14</xref>,<xref rid="b15-copd-12-2179" ref-type="bibr">15</xref> To illustrate the variability of our multiple-breath measurement, <inline-formula><mml:math id="mm17"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> was plotted against time in a subset of the patients defined EFL<sub>T</sub> at baseline with complete visits (N=20).</p></sec><sec sec-type="methods"><title>Study outcomes</title><p>Distance walked during the 6-minute walk test (6MWT) was used to assess exercise performance. The 6MWT was supervised by a trained technician and performed in a 30-m, straight hospital corridor according to agreed standards at baseline and at the end of the study, at the 3-year visit.<xref rid="b24-copd-12-2179" ref-type="bibr">24</xref></p><p>Exacerbations were defined as a worsening of respiratory symptoms over 2 days or more that required systemic corticosteroids or antibiotics, alone or in combination (&#x0201c;moderate exacerbations&#x0201d;), or exacerbations resulting in hospitalization (&#x0201c;severe exacerbations&#x0201d;). Assessment of exacerbations was performed retrospectively by the study physician at the half-yearly visits, over the 3-year study period.</p><p>Mortality statistics were retrieved on August 25, 2011, approximately 5 years after the conclusion of the baseline visit by checking vital status in our local patient file system, which is linked to the Norwegian Causes of Death Registry. The Causes of Death Registry includes deaths of all residents, regardless of whether they die in Norway or abroad, and is assumed to have information on &#x0003e;98% of all deaths.<xref rid="b25-copd-12-2179" ref-type="bibr">25</xref></p></sec><sec><title>Statistics</title><p>IBM SPSS version 22, Stata 13.1, and R 3.2.3 GUI 1.66 were used for different aspects of statistical analyses. Data are presented as mean &#x000b1; standard deviation, median (quartiles), mean (95% confidence interval), and absolute count or percentage. Means were compared using independent samples <italic>t</italic>-tests, paired samples <italic>t</italic>-tests, or Mann&#x02013;Whitney <italic>U</italic> test when appropriate.</p><p>Patients were categorized into three groups according to <inline-formula><mml:math id="mm18"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>: normal, &#x02265; ULN &#x0003c; EFL<sub>T</sub>, and &#x02265; EFL<sub>T</sub> at baseline. We report the change in the 6-minute walk distance in these three groups from baseline to the 3-year visit in notched boxplots. Differences in walking distance between baseline and the end of the study were compared using paired samples <italic>t</italic>-test, grouping the patients according to the <inline-formula><mml:math id="mm19"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade.<xref rid="b2-copd-12-2179" ref-type="bibr">2</xref></p><p>The rate of exacerbations in the three groups was analyzed as suggested by Keene et al using a negative binomial regression model, accounting for the yearly variability among test subjects in the exacerbation rate over the 3-year study period, adjusting for FEV<sub>1</sub>, age, sex, and a binary classifier identifying frequent exacerbators in the year prior to inclusion.<xref rid="b26-copd-12-2179" ref-type="bibr">26</xref> Parameter effects of the baseline explanatory variables are reported as annual rate ratios (RRs), 95% confidence interval (CI), and <italic>P</italic>-values. Moderate and severe exacerbations requiring hospitalization were also investigated on the basis of the occurrence of <inline-formula><mml:math id="mm20"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> at baseline by time to first event analysis. Groups were compared using a log-rank test. Results are displayed as 1-minus-survival plots.</p><p>Survival analysis was performed with Kaplan&#x02013;Meier survival analysis, comparing distributions with the log-rank test, grouping patients by the occurrence of <inline-formula><mml:math id="mm21"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> at baseline, and by dichotomizing FEV<sub>1</sub> at 50% of that predicted.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro"><title>Baseline characteristics</title><p>In this population of patients with COPD, 60% were men and had moderate to very severe airway obstruction. Women were, on average, 2 years younger and had lower tobacco exposure (<xref ref-type="supplementary-material" rid="SD2-copd-12-2179">Table S1</xref>); 50% of patients with COPD had normal <inline-formula><mml:math id="mm22"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, 31% were classified as being abnormal with <inline-formula><mml:math id="mm23"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext><mml:mo>&#x0003c;</mml:mo><mml:msub><mml:mrow><mml:mtext>EFL</mml:mtext></mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, and 18% had <inline-formula><mml:math id="mm24"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> above the threshold of EFL<sub>T</sub> (<xref ref-type="table" rid="t1-copd-12-2179">Table 1</xref>). From the normal to the abnormal group, lung function worsened with a decline in FEV<sub>1</sub> and FVC, and an increase in body mass index (BMI) and mMRC. This difference was most marked between the normal and EFL<sub>T</sub> group. For IC, we only found a significant difference between the normal and the EFL<sub>T</sub> group.</p><p><inline-formula><mml:math id="mm25"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> was not a stable measurement. Many patients defined as EFL<sub>T</sub> at baseline fell below the EFL<sub>T</sub> threshold during the course of the study (<xref ref-type="fig" rid="f1-copd-12-2179">Figure 1</xref>). Six percent of the consequent <inline-formula><mml:math id="mm26"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> measurements were found to be normal; 23% of the patients dropped out of the study before the final visit, the main reason being death during the study period (<xref ref-type="table" rid="t2-copd-12-2179">Table 2</xref>).</p></sec><sec sec-type="methods"><title>Relationship of EFL<sub>T</sub> to study outcomes</title><p><inline-formula><mml:math id="mm27"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> was as poorly correlated with baseline 6-minute walking distance as FEV<sub>1</sub> (<xref ref-type="fig" rid="f2-copd-12-2179">Figure 2A and B</xref>). On a group level, 6MWD declined with increasing <inline-formula><mml:math id="mm28"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, being 455 m in the normal, 410 m in the abnormal, and 363 m in the EFL<sub>T</sub> group (<xref ref-type="table" rid="t1-copd-12-2179">Table 1</xref>). In patients who completed both the baseline and the final visit, changes in 6MWD were compared. No significant change between the baseline and the final 3-year visit was seen in the 6MWD of patients with normal <inline-formula><mml:math id="mm29"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>. Patients with <inline-formula><mml:math id="mm30"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> declined by a mean of 37 m (95% CI 15&#x02013;58), <italic>P</italic>=0.001, and patients with EFL<sub>T</sub> declined by 63 m (95% CI 31&#x02013;95), <italic>P</italic>&#x0003c;0.001 (<xref ref-type="fig" rid="f2-copd-12-2179">Figure 2C</xref>). Grouping by GOLD grade produced similar boxplots. GOLD 2 patients remained stable whereas a significant decline was seen in GOLD 3&#x02013;4 grades (<xref ref-type="fig" rid="f2-copd-12-2179">Figure 2D</xref>).</p><p>A total of 1,289 moderate to severe exacerbations were recorded throughout the study. By negative binomial regression, estimated annual exacerbations rates were 0.7 in patients with normal <inline-formula><mml:math id="mm31"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, 1.3 in patients with COPD with <inline-formula><mml:math id="mm32"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula>, and 1.6 in patients with EFL<sub>T</sub>. Annual exacerbation RR compared to the normal group was 1.28 for ULN patients and 1.30 for EFL<sub>T</sub> patients (<xref ref-type="table" rid="t3-copd-12-2179">Table 3</xref>). A time to first exacerbation analysis was performed in patients with COPD with and without evidence of <inline-formula><mml:math id="mm33"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> at baseline. Significant differences were found in both time to first exacerbation (<italic>P</italic>=0.009) and in time to first hospitalization (<italic>P</italic>=0.017; <xref ref-type="fig" rid="f3-copd-12-2179">Figure 3A</xref>). Median time to first moderate or severe exacerbation was 76 weeks in patients with COPD with normal <inline-formula><mml:math id="mm34"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, compared with only 55 weeks in COPD patients with <inline-formula><mml:math id="mm35"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> at baseline (<xref ref-type="table" rid="t4-copd-12-2179">Table 4</xref>). The time until 25% of the patients were hospitalized was 126 weeks in patients with normal <inline-formula><mml:math id="mm36"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> and 72 weeks in patients with <inline-formula><mml:math id="mm37"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula>.</p></sec><sec><title>Mortality</title><p>At the 5-year census, 72 (17%) of the 425 patients with COPD had died. Deaths were significantly more frequent in patients with &#x02265; ULN than in patients with normal <inline-formula><mml:math id="mm38"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, but not significantly different between the &#x02265; ULN and the EFL<sub>T</sub>, groups (<xref ref-type="table" rid="t1-copd-12-2179">Table 1</xref>). Mortality was higher in patients with FEV<sub>1</sub> &#x0003c;50% (<xref ref-type="fig" rid="f4-copd-12-2179">Figure 4</xref>). The difference in mortality between patients with <inline-formula><mml:math id="mm39"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> in the normal range and &#x02265; ULN was driven by increased mortality in patients with FEV<sub>1</sub> &#x0003e;50% (<xref ref-type="fig" rid="f4-copd-12-2179">Figure 4</xref>). Mortality was 17% in <inline-formula><mml:math id="mm40"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> patients with FEV<sub>1</sub> &#x0003e;50%, compared to 5% in patients with normal &#x00394;Xrs (<italic>P</italic>&#x0003c;0.001; <xref ref-type="fig" rid="f4-copd-12-2179">Figure 4</xref>). Mortality in patients with &#x00394;Xrs &#x02265; ULN was similar to what was found in patients with COPD with much more advanced airway obstruction.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Using data from the ECLIPSE study, we investigated associations between increased <inline-formula><mml:math id="mm41"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> at the ULN and at the threshold of EFL<sub>T</sub> with decline in 6MWD, risk of later exacerbations, and all-cause mortality. No change in 6MWD was found in patients with COPD with <inline-formula><mml:math id="mm42"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> in the normal range. All patients with COPD with <inline-formula><mml:math id="mm43"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> deteriorated significantly in 6MWD. Patients with COPD with <inline-formula><mml:math id="mm44"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> had increased risk for both moderate and severe exacerbations, and, in the patients with only moderate airway obstruction, FEV<sub>1</sub> &#x0003e;50%, a significantly higher mortality. This study Xrs demonstrates that <inline-formula><mml:math id="mm45"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> provides valuable extra information in addition to FEV<sub>1</sub> when characterizing the effects of small-airway obstruction on key COPD outcomes.</p><p>We defined the ULN at the 97.5th percentile of healthy controls included in our study. Data describing the control group have previously been published.<xref rid="b13-copd-12-2179" ref-type="bibr">13</xref>,<xref rid="b18-copd-12-2179" ref-type="bibr">18</xref> The FOT threshold identifying a single flow-limited breath has been defined when within-breath reactance was &#x0003e;0.28 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>.<xref rid="b14-copd-12-2179" ref-type="bibr">14</xref>,<xref rid="b15-copd-12-2179" ref-type="bibr">15</xref> We interpreted our continuous spectrum measurements performed over several breaths as showing evidence of flow limitation when measurements between the ULN and the threshold of EFL<sub>T</sub> were found. These borderline measurements are thought to represent a mixture of normal and flow-limited breaths.</p><p>Exercise limitation is extremely common in COPD, and even small decreases in the 6MWD over time identify patients with increased risks of dying.<xref rid="b27-copd-12-2179" ref-type="bibr">27</xref> When EFL<sub>T</sub> is present, patients can only increase their minute ventilation during exercise by increasing breathing frequency or by dynamic hyperinflation, allowing end-expiratory lung volume to rise.<xref rid="b28-copd-12-2179" ref-type="bibr">28</xref> Dynamic hyperinflation can be induced by self-paced walking exercise. This is usually assessed by changes in operating lung volume.<xref rid="b12-copd-12-2179" ref-type="bibr">12</xref>,<xref rid="b29-copd-12-2179" ref-type="bibr">29</xref> We did not measure lung volume during the 6MWT, but reasoned that patients with COPD showing evidence of flow limitation at baseline, either as having <inline-formula><mml:math id="mm46"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> or the threshold of EFL<sub>T</sub>, were more likely to have a worse exercise tolerance at the same visit. This was true on a group level. The EFL<sub>T</sub> group had the lowest 6MWD, but neither FEV<sub>1</sub> % predicted nor any cut-off level of <inline-formula><mml:math id="mm47"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> could identify patients with COPD with a short walking distance (&#x0003c;350 m), as proposed by Spruit et al.<xref rid="b30-copd-12-2179" ref-type="bibr">30</xref> No significant decline was seen in patients with <inline-formula><mml:math id="mm48"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> in the normal range; in patients with COPD with <inline-formula><mml:math id="mm49"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> it declined 37 m, and in patients with EFL<sub>T</sub>, it declined by 63 m. The minimal clinically important difference on an individual level has been suggested to be 30 m in an ERS/ATS systematic review;<xref rid="b31-copd-12-2179" ref-type="bibr">31</xref> consequently, the differences seen over time between our subgroups defined by <inline-formula><mml:math id="mm50"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> and EFL<sub>T</sub> are likely to be clinically important.</p><p>Exacerbation and hospitalization rates at our site were similar to those reported in the completed ECLIPSE study and in the TORCH study.<xref rid="b32-copd-12-2179" ref-type="bibr">32</xref>,<xref rid="b33-copd-12-2179" ref-type="bibr">33</xref> By negative binomial regression, the <inline-formula><mml:math id="mm51"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>cut-offs</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> and EFL<sub>T</sub> were both significant predictors for higher rates of exacerbations with very similar RR, demonstrating that the increased risk of exacerbations by EFL<sub>T</sub> is identified already at ULN. In the time to first event analysis of patients with <inline-formula><mml:math id="mm52"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula>, we found a shorter time to first exacerbation and a shorter time to first hospitalization than that of the COPD patients with <inline-formula><mml:math id="mm53"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> in the normal range. A previous study on hospitalized patients showed that many, but not all, have FOT-defined EFL<sub>T</sub> during a COPD exacerbation.<xref rid="b17-copd-12-2179" ref-type="bibr">17</xref> FOT measurements performed during hospitalized COPD exacerbations show that <inline-formula><mml:math id="mm54"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> measurements improve during resolution of an exacerbation, although many patients remain EFL<sub>T</sub> at discharge.<xref rid="b17-copd-12-2179" ref-type="bibr">17</xref> At present, there is a shortage of readily measurable biomarkers that can predict the risk of future exacerbations. Our data suggest that, after adjusting for lung function and exacerbation history, EFL<sub>T</sub> measurement can identify patients who are more likely to develop exacerbations. Further prospective studies to confirm these observations and explore their mechanism are merited.</p><p>Patients with COPD with an FEV<sub>1</sub> &#x0003e;50% predicted and evidence of EFL<sub>T</sub>, defined as baseline &#x00394;Xrs &#x02265; ULN, had significantly higher risk of dying within the 5-year follow-up. Similar associations were not found in the patients with more advanced airway obstruction and FEV<sub>1</sub> &#x0003c;50%. However, COPD is a complex, heterogeneous disease, and respiratory impairment is associated with higher incidence of comorbidities, such as hypertension, cardiovascular disease, and diabetes.<xref rid="b34-copd-12-2179" ref-type="bibr">34</xref> If there is an association between <inline-formula><mml:math id="mm55"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> and mortality, the higher risk of adverse outcomes associated with comorbid disease could mask such an association with advanced disease. Although the association between death and <inline-formula><mml:math id="mm56"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> was highly significant, this sub-analysis should be interpreted with caution due to the relatively small number of deaths in patients with FEV<sub>1</sub> &#x0003e;50% predicted (<xref ref-type="table" rid="t1-copd-12-2179">Table 1</xref>).</p><p>There are certain limitations of this study. The FOT threshold identifying a single flow-limited breath has been defined at <inline-formula><mml:math id="mm57"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003e;</mml:mo><mml:mn>0.28</mml:mn><mml:mspace width="0.2em"/><mml:mtext>kPa</mml:mtext><mml:mo>&#x022c5;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi mathvariant="normal">L</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>.<xref rid="b14-copd-12-2179" ref-type="bibr">14</xref>,<xref rid="b15-copd-12-2179" ref-type="bibr">15</xref> It is not known whether the use of this threshold may lead to different results when applied to values measured over a continuous spectrum of several breaths. Previously published data show that the end-expiratory lung volume varies from breath-to-breath, affecting the prevalence of EFL<sub>T</sub>.<xref rid="b8-copd-12-2179" ref-type="bibr">8</xref>,<xref rid="b15-copd-12-2179" ref-type="bibr">15</xref> Although the prevalence of EFL<sub>T</sub> increased as the FEV<sub>1</sub>% predicted declined, not all patients with very severe airway obstruction were found to have EFL<sub>T</sub>. In previous studies on elderly and COPD with the NEP technique, higher prevalence of EFL<sub>T</sub> have been reported than in the present study.<xref rid="b11-copd-12-2179" ref-type="bibr">11</xref>,<xref rid="b35-copd-12-2179" ref-type="bibr">35</xref>,<xref rid="b36-copd-12-2179" ref-type="bibr">36</xref> Different inclusion criteria and differences in sensitivity between the NEP and the FOT technique, together with the possibility that in borderline patients the application of a NEP per se could lead to development of EFL<sub>T</sub>, are likely explanations. The wide reference range of FEV<sub>1</sub> inevitably may also lead to an overestimation of the suspected lung function decline in many patients.<xref rid="b23-copd-12-2179" ref-type="bibr">23</xref></p><p>As previously noted, EFL<sub>T</sub> varies between breaths in many patients with COPD and varies with repeat testing, likely reflecting differences in the end-expiratory lung volume on different test days.<xref rid="b13-copd-12-2179" ref-type="bibr">13</xref> Physiological variability in these measurements might require the repetition of this test in different periods to increase the sensitivity of our test. Despite this limitation, important relationships related to the presence of tidal flow limitation were seen, even when the data were controlled for severity of airflow obstruction measured by FEV<sub>1</sub>. The data reflect results from the largest recruiting center in the ECLIPSE study, in which patients were carefully characterized using standardized methodologies including oscillatory mechanics.<xref rid="b18-copd-12-2179" ref-type="bibr">18</xref>,<xref rid="b37-copd-12-2179" ref-type="bibr">37</xref></p></sec><sec><title>Conclusion</title><p>Consistent differences in clinically relevant outcomes were found, such as exercise capability, exacerbations, hospitalizations, and death in COPD patients with baseline <inline-formula><mml:math id="mm58"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="true">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> beyond the ULN. This is below the established threshold for EFL<sub>T</sub>. Our data support previous studies showing that patients with EFL<sub>T</sub> have worse lung mechanics than is evident from FEV<sub>1</sub> measurement alone.<xref rid="b11-copd-12-2179" ref-type="bibr">11</xref>,<xref rid="b38-copd-12-2179" ref-type="bibr">38</xref> The present study suggests that evidence of EFL<sub>T</sub>, measured during tidal breathing in an effort-independent fashion, can identify a subgroup of COPD patients with worse clinical outcomes.</p></sec><sec sec-type="supplementary-material"><title>Supplementary materials</title><supplementary-material content-type="local-data" id="SD1-copd-12-2179"><label>Figure S1</label><caption><p>Scatterplot of <inline-formula><mml:math id="mm59"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> plotted against FEV<sub>1</sub> % predicted in healthy controls (N=229). Mean represented by the solid line. The dashed line represents the 97.5th percentile, the upper limit of normal (ULN).</p></caption><media mimetype="image" mime-subtype="tif" xlink:href="copd-12-2179s1.tif" xlink:type="simple" id="d35e1682" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2-copd-12-2179"><table-wrap id="ts1-copd-12-2179" position="float"><label>Table S1</label><caption><p>Baseline characteristics in men and women (N=425)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Subject characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">Total</th><th valign="top" align="left" rowspan="1" colspan="1">Men</th><th valign="top" align="left" rowspan="1" colspan="1">Women</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Subjects (n)</td><td valign="top" align="left" rowspan="1" colspan="1">425</td><td valign="top" align="left" rowspan="1" colspan="1">254</td><td valign="top" align="left" rowspan="1" colspan="1">171</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">63 (7)</td><td valign="top" align="left" rowspan="1" colspan="1">64 (7)</td><td valign="top" align="left" rowspan="1" colspan="1">62 (7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI kg/m<sup>2</sup></td><td valign="top" align="left" rowspan="1" colspan="1">25 (5)</td><td valign="top" align="left" rowspan="1" colspan="1">26 (5)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (6)</td><td valign="top" align="left" rowspan="1" colspan="1">ns</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pack-years (years)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (23)</td><td valign="top" align="left" rowspan="1" colspan="1">45 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">mMRC</td><td valign="top" align="left" rowspan="1" colspan="1">1.6 (1, 2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.6 (1, 2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.7 (1, 2)</td><td valign="top" align="left" rowspan="1" colspan="1">ns</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (L)</td><td valign="top" align="left" rowspan="1" colspan="1">1.5 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1.6 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.3 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (14)</td><td valign="top" align="left" rowspan="1" colspan="1">45 (14)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (13)</td><td valign="top" align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FVC (L)</td><td valign="top" align="left" rowspan="1" colspan="1">3.3 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3.7 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2.6 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="mm69"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003e;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mspace width="0.2em"/><mml:mtext>kPa</mml:mtext><mml:mo>&#x022c5;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi mathvariant="normal">L</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula></td><td valign="top" align="left" rowspan="1" colspan="1">0.14 (0.17)</td><td valign="top" align="left" rowspan="1" colspan="1">0.13 (0.14)</td><td valign="top" align="left" rowspan="1" colspan="1">0.16 (0.20)</td><td valign="top" align="left" rowspan="1" colspan="1">ns</td></tr></tbody></table><table-wrap-foot><fn id="tfn12-copd-12-2179"><p><bold>Note:</bold> Data presented as mean (standard deviation) unless otherwise stated.</p></fn><fn id="tfn13-copd-12-2179"><p><bold>Abbreviations:</bold> ULN, upper limit of normal 0.09 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>; EFL<sub>T</sub>, tidal expiratory flow limitation; BMI, body mass index; Pack-years, packs of 20 cigarettes smoked per day &#x000d7; years as a smoker; Frequent exacerbators, percentage with &#x02265;2 exacerbations the year the prior to inclusion; mMRC, modified Medical Research Council dyspnea scale score &#x02013; mean (quartiles); FEV<sub>1</sub>, forced expiratory volume in 1 second; FEV<sub>1</sub> (%), FEV<sub>1</sub> percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), IC percentage of predicted; <inline-formula><mml:math id="mm70"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, difference between mean inspiratory and mean expiratory reactance at 5 Hz over multiple breaths; 6MWD, 6-minute walk distance.</p></fn></table-wrap-foot></table-wrap></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The study was sponsored by GlaxoSmithKline. The sponsor had no role in the design of the study, collection and analysis of the data, nor in the preparation of the manuscript.</p><p>The work was performed at Haukeland University Hospital. The authors thank all participants who took part in the study, all members of the Bergen Respiratory Research Group who contributed to the data collection, and offer special thanks to Lene Svendsen, Rita Oppedal, Tina Endresen-Vinsjevik, and Eli Nordeide who performed/supervised the pulmonary function tests.</p></ack><fn-group><fn><p><bold>Author contributions</bold></p><p>The corresponding author BBA wrote the manuscript, had access to all of the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. PMAC was in the ECLIPSE Scientific Committee and PSB in the ECLIPSE Steering Committee. They both contributed to the development of the research design. PSB, JAH, and TMLE also contributed in the data collection. All authors, including RLJ and RD, contributed to the data analysis, the clinical interpretation of the data, and to reviewing the final submission.</p></fn><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-12-2179"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Foreman</surname><given-names>K</given-names></name><etal/></person-group><article-title>Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><issue>9859</issue><fpage>2095</fpage><lpage>2128</lpage><pub-id pub-id-type="pmid">23245604</pub-id></element-citation></ref><ref id="b2-copd-12-2179"><label>2</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>From the Global Strategy for the Diagnosis, Management and Prevention of COPD</collab></person-group><source>Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/">http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/</ext-link></comment><date-in-citation>Accessed April 18, 2017</date-in-citation></element-citation></ref><ref id="b3-copd-12-2179"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soriano</surname><given-names>JB</given-names></name><name><surname>Alfageme</surname><given-names>I</given-names></name><name><surname>Almagro</surname><given-names>P</given-names></name><etal/></person-group><article-title>Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification</article-title><source>Chest</source><year>2013</year><volume>143</volume><issue>3</issue><fpage>694</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">23187891</pub-id></element-citation></ref><ref id="b4-copd-12-2179"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franciosi</surname><given-names>LG</given-names></name><name><surname>Page</surname><given-names>CP</given-names></name><name><surname>Celli</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Markers of disease severity in chronic obstructive pulmonary disease</article-title><source>Pulm Pharmacol Ther</source><year>2006</year><volume>19</volume><issue>3</issue><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">16019244</pub-id></element-citation></ref><ref id="b5-copd-12-2179"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelb</surname><given-names>AF</given-names></name><name><surname>Hogg</surname><given-names>JC</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>NL</given-names></name><etal/></person-group><article-title>Contribution of emphysema and small airways in COPD</article-title><source>Chest</source><year>1996</year><volume>109</volume><issue>2</issue><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">8620705</pub-id></element-citation></ref><ref id="b6-copd-12-2179"><label>6</label><element-citation publication-type="webpage"><source>Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011</source><year>2011</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.org">www.goldcopd.org</ext-link></comment><date-in-citation>Accessed January 2, 2012</date-in-citation></element-citation></ref><ref id="b7-copd-12-2179"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyatt</surname><given-names>RE</given-names></name></person-group><article-title>The interrelationships of pressure, flow, and volume during various respiratory maneuvers in normal and emphysematous subjects</article-title><source>Am Rev Respir Dis</source><year>1961</year><volume>83</volume><fpage>676</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">13717137</pub-id></element-citation></ref><ref id="b8-copd-12-2179"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name></person-group><article-title>Ventilatory limitations in chronic obstructive pulmonary disease</article-title><source>Med Sci Sports Exerc</source><year>2001</year><volume>33</volume><issue>7 Suppl</issue><fpage>S647</fpage><lpage>S655</lpage><pub-id pub-id-type="pmid">11462073</pub-id></element-citation></ref><ref id="b9-copd-12-2179"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Koulouris</surname><given-names>NG</given-names></name></person-group><article-title>Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology</article-title><source>Eur Respir J</source><year>2005</year><volume>25</volume><issue>1</issue><fpage>186</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">15640341</pub-id></element-citation></ref><ref id="b10-copd-12-2179"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>O</given-names></name><name><surname>Villafranca</surname><given-names>C</given-names></name><name><surname>Ghezzo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest</article-title><source>Eur Respir J</source><year>2000</year><volume>16</volume><issue>2</issue><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">10968502</pub-id></element-citation></ref><ref id="b11-copd-12-2179"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eltayara</surname><given-names>L</given-names></name><name><surname>Becklake</surname><given-names>MR</given-names></name><name><surname>Volta</surname><given-names>CA</given-names></name><name><surname>Milic-Emili</surname><given-names>J</given-names></name></person-group><article-title>Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>154</volume><issue>6 Pt 1</issue><fpage>1726</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">8970362</pub-id></element-citation></ref><ref id="b12-copd-12-2179"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Webb</surname><given-names>KA</given-names></name></person-group><article-title>Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation</article-title><source>Am Rev Respir Dis</source><year>1993</year><volume>148</volume><issue>5</issue><fpage>1351</fpage><lpage>1357</lpage><pub-id pub-id-type="pmid">8239175</pub-id></element-citation></ref><ref id="b13-copd-12-2179"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarli</surname><given-names>BB</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Jensen</surname><given-names>RL</given-names></name><name><surname>Eagan</surname><given-names>TM</given-names></name><name><surname>Bakke</surname><given-names>PS</given-names></name><name><surname>Hardie</surname><given-names>JA</given-names></name></person-group><article-title>Variability of within-breath reactance in COPD patients and its association with dyspnoea</article-title><source>Eur Respir J</source><year>2015</year><volume>45</volume><issue>3</issue><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">25359342</pub-id></element-citation></ref><ref id="b14-copd-12-2179"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellac&#x000e0;</surname><given-names>RL</given-names></name><name><surname>Duffy</surname><given-names>N</given-names></name><name><surname>Pompilio</surname><given-names>PP</given-names></name><etal/></person-group><article-title>Expiratory flow limitation detected by forced oscillation and negative expiratory pressure</article-title><source>Eur Respir J</source><year>2007</year><volume>29</volume><issue>2</issue><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">17079262</pub-id></element-citation></ref><ref id="b15-copd-12-2179"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellac&#x000e0;</surname><given-names>RL</given-names></name><name><surname>Santus</surname><given-names>P</given-names></name><name><surname>Aliverti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Detection of expiratory flow limitation in COPD using the forced oscillation technique</article-title><source>Eur Respir J</source><year>2004</year><volume>23</volume><issue>2</issue><fpage>232</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">14979497</pub-id></element-citation></ref><ref id="b16-copd-12-2179"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Laveneziana</surname><given-names>P</given-names></name></person-group><article-title>Dyspnea and activity limitation in COPD: mechanical factors</article-title><source>COPD</source><year>2007</year><volume>4</volume><issue>3</issue><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">17729066</pub-id></element-citation></ref><ref id="b17-copd-12-2179"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jetmalani</surname><given-names>K</given-names></name><name><surname>Timmins</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Expiratory flow limitation relates to symptoms during COPD exacerbations requiring hospital admission</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2015</year><volume>10</volume><fpage>939</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">25999709</pub-id></element-citation></ref><ref id="b18-copd-12-2179"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>W</given-names></name><name><surname>Coxson</surname><given-names>HO</given-names></name><etal/><collab>ECLIPSE investigators</collab></person-group><article-title>Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE)</article-title><source>Eur Respir J</source><year>2008</year><volume>31</volume><issue>4</issue><fpage>869</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">18216052</pub-id></element-citation></ref><ref id="b19-copd-12-2179"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Wells</surname><given-names>CK</given-names></name></person-group><article-title>Evaluation of clinical methods for rating dyspnea</article-title><source>Chest</source><year>1988</year><volume>93</volume><issue>3</issue><fpage>580</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">3342669</pub-id></element-citation></ref><ref id="b20-copd-12-2179"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname><given-names>BG</given-names></name></person-group><article-title>Epidemiology Standardization Project (American Thoracic Society)</article-title><source>Am Rev Respir Dis</source><year>1978</year><volume>118</volume><issue>6 Pt 2</issue><fpage>1</fpage><lpage>120</lpage></element-citation></ref><ref id="b21-copd-12-2179"><label>21</label><element-citation publication-type="journal"><article-title>Standardization of spirometry, 1994 update. American Thoracic Society</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>152</volume><issue>3</issue><fpage>1107</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">7663792</pub-id></element-citation></ref><ref id="b22-copd-12-2179"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostveen</surname><given-names>E</given-names></name><name><surname>MacLeod</surname><given-names>D</given-names></name><name><surname>Lorino</surname><given-names>H</given-names></name><etal/><collab>ERS Task Force on Respiratory Impedance Measurements</collab></person-group><article-title>The forced oscillation technique in clinical practice: methodology, recommendations and future developments</article-title><source>Eur Respir J</source><year>2003</year><volume>22</volume><issue>6</issue><fpage>1026</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">14680096</pub-id></element-citation></ref><ref id="b23-copd-12-2179"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulsvik</surname><given-names>A</given-names></name><name><surname>Tosteson</surname><given-names>T</given-names></name><name><surname>Bakke</surname><given-names>P</given-names></name><name><surname>Humerfelt</surname><given-names>S</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Speizer</surname><given-names>FE</given-names></name></person-group><article-title>Expiratory and inspiratory forced vital capacity and one-second forced volume in asymptomatic never-smokers in Norway</article-title><source>Clin Physiol</source><year>2001</year><volume>21</volume><issue>6</issue><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">11722472</pub-id></element-citation></ref><ref id="b24-copd-12-2179"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories</collab></person-group><article-title>ATS statement: guidelines for the six-minute walk test</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><issue>1</issue><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">12091180</pub-id></element-citation></ref><ref id="b25-copd-12-2179"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>AG</given-names></name><name><surname>Ellingsen</surname><given-names>CL</given-names></name></person-group><article-title>Data quality in the Causes of Death Registry</article-title><source>Tidsskr Nor Laegeforen</source><year>2015</year><volume>135</volume><issue>8</issue><fpage>768</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">25947599</pub-id></element-citation></ref><ref id="b26-copd-12-2179"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keene</surname><given-names>ON</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name></person-group><article-title>Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited</article-title><source>Eur Respir J</source><year>2008</year><volume>32</volume><issue>1</issue><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">18591336</pub-id></element-citation></ref><ref id="b27-copd-12-2179"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polkey</surname><given-names>MI</given-names></name><name><surname>Spruit</surname><given-names>MA</given-names></name><name><surname>Edwards</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization</article-title><source>Am J Respir Crit Care Med</source><year>2013</year><volume>187</volume><issue>4</issue><fpage>382</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">23262518</pub-id></element-citation></ref><ref id="b28-copd-12-2179"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guenette</surname><given-names>JA</given-names></name><name><surname>Webb</surname><given-names>KA</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name></person-group><article-title>Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD?</article-title><source>Eur Respir J</source><year>2012</year><volume>40</volume><issue>2</issue><fpage>322</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">22183485</pub-id></element-citation></ref><ref id="b29-copd-12-2179"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>JM</given-names></name><name><surname>Carrizo</surname><given-names>SJ</given-names></name><name><surname>Gascon</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>A</given-names></name><name><surname>Gallego</surname><given-names>B</given-names></name><name><surname>Celli</surname><given-names>BR</given-names></name></person-group><article-title>Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><issue>6</issue><fpage>1395</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">11371407</pub-id></element-citation></ref><ref id="b30-copd-12-2179"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruit</surname><given-names>MA</given-names></name><name><surname>Polkey</surname><given-names>MI</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><etal/><collab>Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators</collab></person-group><article-title>Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease</article-title><source>J Am Med Dir Assoc</source><year>2012</year><volume>13</volume><issue>3</issue><fpage>291</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">21778120</pub-id></element-citation></ref><ref id="b31-copd-12-2179"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SJ</given-names></name><name><surname>Puhan</surname><given-names>MA</given-names></name><name><surname>Andrianopoulos</surname><given-names>V</given-names></name><etal/></person-group><article-title>An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease</article-title><source>Eur Respir J</source><year>2014</year><volume>44</volume><issue>6</issue><fpage>1447</fpage><lpage>1478</lpage><pub-id pub-id-type="pmid">25359356</pub-id></element-citation></ref><ref id="b32-copd-12-2179"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal/><collab>Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators</collab></person-group><article-title>Susceptibility to exacerbation in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>12</issue><fpage>1128</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">20843247</pub-id></element-citation></ref><ref id="b33-copd-12-2179"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>CR</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study</article-title><source>Respir Res</source><year>2009</year><volume>10</volume><fpage>59</fpage><pub-id pub-id-type="pmid">19566934</pub-id></element-citation></ref><ref id="b34-copd-12-2179"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Thorn</surname><given-names>D</given-names></name><name><surname>Swensen</surname><given-names>A</given-names></name><name><surname>Holguin</surname><given-names>F</given-names></name></person-group><article-title>Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD</article-title><source>Eur Respir J</source><year>2008</year><volume>32</volume><issue>4</issue><fpage>962</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">18579551</pub-id></element-citation></ref><ref id="b35-copd-12-2179"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bisschop</surname><given-names>C</given-names></name><name><surname>Marty</surname><given-names>ML</given-names></name><name><surname>Tessier</surname><given-names>JF</given-names></name><name><surname>Barberger-Gateau</surname><given-names>P</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Gu&#x000e9;nard</surname><given-names>H</given-names></name></person-group><article-title>Expiratory flow limitation and obstruction in the elderly</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><issue>4</issue><fpage>594</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">16204588</pub-id></element-citation></ref><ref id="b36-copd-12-2179"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koulouris</surname><given-names>NG</given-names></name><name><surname>Valta</surname><given-names>P</given-names></name><name><surname>Lavoie</surname><given-names>A</given-names></name><etal/></person-group><article-title>A simple method to detect expiratory flow limitation during spontaneous breathing</article-title><source>Eur Respir J</source><year>1995</year><volume>8</volume><issue>2</issue><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">7758567</pub-id></element-citation></ref><ref id="b37-copd-12-2179"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crim</surname><given-names>C</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Edwards</surname><given-names>LD</given-names></name><etal/><collab>ECLIPSE investigators</collab></person-group><article-title>Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results</article-title><source>Respir Med</source><year>2011</year><volume>105</volume><issue>7</issue><fpage>1069</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">21481577</pub-id></element-citation></ref><ref id="b38-copd-12-2179"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Bertley</surname><given-names>JC</given-names></name><name><surname>Chau</surname><given-names>LK</given-names></name><name><surname>Webb</surname><given-names>KA</given-names></name></person-group><article-title>Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>155</volume><issue>1</issue><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">9001298</pub-id></element-citation></ref><ref id="b39-copd-12-2179"><label>39</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>GlaxoSmithKline</collab></person-group><source>Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE)</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT00292552?">https://clinicaltrials.gov/show/NCT00292552?</ext-link>. NLM identifier: NCT00292552</comment><date-in-citation>Accessed April 4, 2017</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig id="f1-copd-12-2179" position="float"><label>Figure 1</label><caption><p>Timeplot illustrating the variability of <inline-formula><mml:math id="mm60"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> measurements (splines) over the course of the study shown in the first 20 patients with COPD with complete visits, defined as having EFL<sub>T</sub> at baseline <inline-formula><mml:math id="mm61"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003e;</mml:mo><mml:mn>0.28</mml:mn><mml:mspace width="0.2em"/><mml:mtext>kPa</mml:mtext><mml:mo>&#x022c5;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi mathvariant="normal">L</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. The dotted line is set at 0.09 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>, the upper limit of normal and the solid line at EFL<sub>T</sub>.</p></caption><graphic xlink:href="copd-12-2179Fig1"/></fig><fig id="f2-copd-12-2179" position="float"><label>Figure 2</label><caption><p>(<bold>A</bold>) Six-minute walk distance (6MWD) in patients with COPD (N=388) at different levels of FEV<sub>1</sub>% predicted (<bold>A</bold>) and <inline-formula><mml:math id="mm62"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> (<bold>B</bold>) at baseline. Dotted lines set at 350 m (horizontal) and at <inline-formula><mml:math id="mm63"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003e;</mml:mo><mml:mn>0.09</mml:mn><mml:mspace width="0.2em"/><mml:mtext>kPa</mml:mtext><mml:mo>&#x022c5;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi mathvariant="normal">L</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, upper limit of normal (ULN), and <inline-formula><mml:math id="mm64"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003e;</mml:mo><mml:mn>0.28</mml:mn><mml:mspace width="0.2em"/><mml:mtext>kPa</mml:mtext><mml:mo>&#x022c5;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi mathvariant="normal">L</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, the threshold for tidal expiratory flow limitation (EFL<sub>T</sub>). The solid lines represent the regression lines. (<bold>C</bold>) 6MWT at baseline and the 3-year visit presented by notchplots with quartiles, 95% central range and outliers among COPD patients of GOLD II&#x02013;IV grades and categorized according to <inline-formula><mml:math id="mm65"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> (<bold>D</bold>) as normal (white), below EFL<sub>T</sub>, but above ULN (light gray), and &#x0003e; EFL<sub>T</sub> threshold (gray). Non-overlapping notched areas are likely to represent significant differences between groups. Solid lines are drawn between the mean 6MWD at baseline and the 3-year visit.</p></caption><graphic xlink:href="copd-12-2179Fig2"/></fig><fig id="f3-copd-12-2179" position="float"><label>Figure 3</label><caption><p>Time to first moderate or severe exacerbation (<bold>A</bold>) and to the first hospitalization (<bold>B</bold>) in COPD patients with <inline-formula><mml:math id="mm66"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> measurements above the upper limit of normal (ULN), 0.9 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup> (solid line), and below the ULN at the baseline visit. Dashed line at 25%.</p></caption><graphic xlink:href="copd-12-2179Fig3"/></fig><fig id="f4-copd-12-2179" position="float"><label>Figure 4</label><caption><p>Kaplan&#x02013;Meier survival curves in COPD patients with normal <inline-formula><mml:math id="mm67"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> and in COPD patients with <inline-formula><mml:math id="mm68"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> measurements above the upper limit of normal (ULN). Test of equality of survival distributions was performed using log-rank test.</p></caption><graphic xlink:href="copd-12-2179Fig4"/></fig><table-wrap id="t1-copd-12-2179" position="float"><label>Table 1</label><caption><p>Baseline characteristics in COPD patients with different levels of <inline-formula><mml:math id="mm71"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> (N=425)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Subject characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">Normal
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Abnormal
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">EFL<sub>T</sub>
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="mm72"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003c;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula></th><th valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="mm73"><mml:mrow><mml:mtext>ULN</mml:mtext><mml:mo>&#x02265;</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003c;</mml:mo><mml:msub><mml:mrow><mml:mtext>EFL</mml:mtext></mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula></th><th valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="mm74"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003e;</mml:mo><mml:mn>0.28</mml:mn><mml:mspace width="0.2em"/><mml:mtext>kPa</mml:mtext><mml:mo>&#x022c5;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi mathvariant="normal">L</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Subjects (n)</td><td valign="top" align="left" rowspan="1" colspan="1">213 (50%)</td><td valign="top" align="left" rowspan="1" colspan="1">134 (32%)</td><td valign="top" align="left" rowspan="1" colspan="1">78 (18%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Women</td><td valign="top" align="left" rowspan="1" colspan="1">40%</td><td valign="top" align="left" rowspan="1" colspan="1">36%</td><td valign="top" align="left" rowspan="1" colspan="1">49%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">63 (7)</td><td valign="top" align="left" rowspan="1" colspan="1">64 (7)</td><td valign="top" align="left" rowspan="1" colspan="1">63 (6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI kg/m<sup>2</sup></td><td valign="top" align="left" rowspan="1" colspan="1">24 (5)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">26 (5)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">28 (6)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pack-years (years)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">43 (22)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (22)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequent exacerbators (%)</td><td valign="top" align="left" rowspan="1" colspan="1">13%</td><td valign="top" align="left" rowspan="1" colspan="1">20%</td><td valign="top" align="left" rowspan="1" colspan="1">35%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">mMRC</td><td valign="top" align="left" rowspan="1" colspan="1">1.2 (0, 2)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.8 (0.25, 2)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">2.3 (1, 2)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (L)</td><td valign="top" align="left" rowspan="1" colspan="1">1.7 (0.5)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.3 (0.5)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.1 (0.4)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (11)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">42 (12)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">38 (13)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FVC (L)</td><td valign="top" align="left" rowspan="1" colspan="1">3.5 (0.9)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">3.2 (0.8)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.9)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IC (L)</td><td valign="top" align="left" rowspan="1" colspan="1">2.6 (0.8)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">2.5 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2.3 (0.7)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IC (%)</td><td valign="top" align="left" rowspan="1" colspan="1">88 (19)</td><td valign="top" align="left" rowspan="1" colspan="1">85 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">84 (21)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6MWD (meters)</td><td valign="top" align="left" rowspan="1" colspan="1">455 (102)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">410 (109)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">363 (110)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref>,<xref ref-type="table-fn" rid="tfn6-copd-12-2179">e</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Estimated exacerbations per year<xref ref-type="table-fn" rid="tfn2-copd-12-2179">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.7</td><td valign="top" align="left" rowspan="1" colspan="1">1.3</td><td valign="top" align="left" rowspan="1" colspan="1">1.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Deaths<xref ref-type="table-fn" rid="tfn3-copd-12-2179">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">25 (12)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref>,<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">28 (21)<xref ref-type="table-fn" rid="tfn4-copd-12-2179">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">18 (23)<xref ref-type="table-fn" rid="tfn5-copd-12-2179">d</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-12-2179"><p><bold>Notes:</bold> Data presented as mean &#x000b1; standard deviation unless otherwise stated.</p></fn><fn id="tfn2-copd-12-2179"><label>a</label><p>Estimated exacerbation rate by negative binomial model.</p></fn><fn id="tfn3-copd-12-2179"><label>b</label><p>Number of deaths at the 5-year census (%). Significant differences at the 5% level are marked as</p></fn><fn id="tfn4-copd-12-2179"><label>c</label><p>between normal and abnormal,</p></fn><fn id="tfn5-copd-12-2179"><label>d</label><p>between normal and EFL<sub>T</sub>, and</p></fn><fn id="tfn6-copd-12-2179"><label>e</label><p>between abnormal and EFL<sub>T</sub>. pack-years: packs of 20 cigarettes smoked per day &#x000d7; years as a smoker; Frequent exacerbators: percentage with &#x02265;2 exacerbations the year the prior to inclusion.</p></fn><fn id="tfn7-copd-12-2179"><p><bold>Abbreviations:</bold> ULN, upper limit of normal 0.09 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>; EFL<sub>T</sub>, tidal expiratory flow limitation; BMI, body mass index; mMRC, modified Medical Research Council dyspnea scale score &#x02013; mean (quartiles); FEV<sub>1</sub>, forced expiratory volume in 1 second; FEV<sub>1</sub> (%), FEV<sub>1</sub> percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), IC percentage of predicted; <inline-formula><mml:math id="mm75"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, difference between mean inspiratory and mean expiratory reactance at 5 Hz over multiple breaths; 6MWD, 6-minute walk distance.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-12-2179" position="float"><label>Table 2</label><caption><p>Deaths and dropouts during the 3-year study period (N=96)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Reason</th><th valign="top" align="left" rowspan="1" colspan="1">N</th><th valign="top" align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Died</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FOT not performed at the final visit</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Refused further participation</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excluded due to use of oral steroids</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excluded after being diagnosed with pulmonary cancer</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other causes</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="left" rowspan="1" colspan="1">96</td><td valign="top" align="left" rowspan="1" colspan="1">23</td></tr></tbody></table><table-wrap-foot><fn id="tfn8-copd-12-2179"><p><bold>Abbreviation:</bold> FOT, forced oscillation technique.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-copd-12-2179" position="float"><label>Table 3</label><caption><p>Annual rate ratios estimated by negative binomial regression (N=395)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Baseline explanatory variables</th><th valign="top" align="left" rowspan="1" colspan="1">RR</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="4" valign="top" align="left" rowspan="1"><inline-formula><mml:math id="mm76"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02265;ULN (0.09 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>) and &#x0003c;EFL<sub>T</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1.28</td><td valign="top" align="left" rowspan="1" colspan="1">1.05, 1.55</td><td valign="top" align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02265;EFL<sub>T</sub> (0.28 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">1.30</td><td valign="top" align="left" rowspan="1" colspan="1">1.05, 1.64</td><td valign="top" align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> % predicted</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td><td valign="top" align="left" rowspan="1" colspan="1">0.04, 0.14</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age in decades</td><td valign="top" align="left" rowspan="1" colspan="1">1.36</td><td valign="top" align="left" rowspan="1" colspan="1">1.06, 1.34</td><td valign="top" align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex (male)</td><td valign="top" align="left" rowspan="1" colspan="1">0.85</td><td valign="top" align="left" rowspan="1" colspan="1">0.72, 1.00</td><td valign="top" align="left" rowspan="1" colspan="1">0.048</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">Exacerbation in the year prior to inclusion</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02265;2</td><td valign="top" align="left" rowspan="1" colspan="1">1.99</td><td valign="top" align="left" rowspan="1" colspan="1">1.64, 2.41</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intercept</td><td valign="top" align="left" rowspan="1" colspan="1">0.98</td><td valign="top" align="left" rowspan="1" colspan="1">0.42, 2.27</td><td valign="top" align="left" rowspan="1" colspan="1">0.965</td></tr></tbody></table><table-wrap-foot><fn id="tfn9-copd-12-2179"><p><bold>Abbreviations:</bold> RR, estimated rate ratio; 95% CI, confidence interval; ULN, upper limit of normal 0.09 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>; EFL<sub>T</sub>, tidal expiratory flow limitation; FEV<sub>1</sub>, forced expiratory volume in 1 second; FEV<sub>1</sub> (%), FEV<sub>1</sub> percentage of predicted.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-copd-12-2179" position="float"><label>Table 4</label><caption><p>Exacerbations, hospitalizations, and deaths in COPD patients with and without <inline-formula><mml:math id="mm77"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula> at baseline (N=425)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Parameter</th><th valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="mm78"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x0003c;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula></th><th valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="mm79"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mtext>ULN</mml:mtext></mml:mrow></mml:math></inline-formula></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Total N</bold></td><td valign="top" align="left" rowspan="1" colspan="1">213</td><td valign="top" align="left" rowspan="1" colspan="1">212</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">N patients (%) with exacerbation</td><td valign="top" align="left" rowspan="1" colspan="1">144 (68%)</td><td valign="top" align="left" rowspan="1" colspan="1">152 (72%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Median time (weeks) to first exacerbation (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">76 (57, 95)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (42, 68)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Log-rank test</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.009</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">N patients (%) hospitalized</td><td valign="top" align="left" rowspan="1" colspan="1">62 (29%)</td><td valign="top" align="left" rowspan="1" colspan="1">84 (40%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Time (weeks) until 25% of the patients were hospitalized</td><td valign="top" align="left" rowspan="1" colspan="1">126</td><td valign="top" align="left" rowspan="1" colspan="1">72</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Log-rank test</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.017</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">N dead at 5-year follow-up</td><td valign="top" align="left" rowspan="1" colspan="1">25 (12%)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (22%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Log-rank test</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.011</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn10-copd-12-2179"><p><bold>Note:</bold> ULN defined at <inline-formula><mml:math id="mm80"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mover accent="true"><mml:mrow><mml:mtext>Xrs</mml:mtext></mml:mrow><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover><mml:mo>&#x02265;</mml:mo><mml:mn>0.09</mml:mn><mml:mspace width="0.2em"/><mml:mtext>kPa</mml:mtext><mml:mo>&#x022c5;</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi mathvariant="normal">L</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>.</p></fn><fn id="tfn11-copd-12-2179"><p><bold>Abbreviations:</bold> ULN, upper limit of normal 0.09 kPa&#x000b7;s&#x000b7;L<sup>&#x02212;1</sup>; 95% CI, 95% confidence interval.</p></fn></table-wrap-foot></table-wrap></floats-group></article>